Inogen | INGN - Current Liabilities


Inogen reported $64.94M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Accuray USD 199.44M 4.83M Dec/2025
AngioDynamics USD 71.96M 3.68M Sep/2025
Artivion USD 92.7M 8.86M Mar/2026
AtriCure USD 73.19M 8.33M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Boston Scientific USD 4.57B 868M Mar/2026
Chart Industries USD 1.87B 253.9M Mar/2026
Cooper Companies USD 1.6B 482.9M Dec/2025
Dexcom USD 2.22B 81.3M Mar/2026
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
Globus Medical USD 482.46M 16.04M Mar/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 687.5M 7.4M Mar/2026
Masimo USD 325.4M 46.2M Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Orthofix International USD 161.03M 9.45M Mar/2026
Philips EUR 7.43B 78M Mar/2026
ResMed USD 1.35B 103.1M Mar/2026
Steris USD 1.14B 222.7M Mar/2026
Stryker USD 6.32B 1.48B Mar/2026
Tandem Diabetes Care USD 247.96M 5.24M Mar/2026
Teleflex USD 728.05M 33.98M Mar/2026
X T L Biopharmaceuticals USD 761K 1.45M Jun/2025
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026